<code id='16B307C296'></code><style id='16B307C296'></style>

<acronym id='16B307C296'></acronym>

<center id='16B307C296'><center id='16B307C296'><tfoot id='16B307C296'></tfoot></center><abbr id='16B307C296'><dir id='16B307C296'><tfoot id='16B307C296'></tfoot><noframes id='16B307C296'>

<optgroup id='16B307C296'><strike id='16B307C296'><sup id='16B307C296'></sup></strike><code id='16B307C296'></code></optgroup>

<b id='16B307C296'><label id='16B307C296'><select id='16B307C296'><dt id='16B307C296'><span id='16B307C296'></span></dt></select></label></b><u id='16B307C296'></u>

~~<i id='16B307C296'><strike id='16B307C296'><tt id='16B307C296'><pre id='16B307C296'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

explore

author：knowledge 2025-10-06 09:54:19 Page View：633

Franklin faces — Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cloning humans is technically possible. It's curious no one has tried
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Cloning humans is technically possible. It's curious no one has tried

Cloning humans is technically possible. It's curious no one has tried

Seven-month-oldDollyposesforphotographsin1997attheUniversityofEdinburgh'sRoslinInstitute,whereshewas

Walensky prepares to leave CDC — and Congress — behind

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Paxlovid study fails to answer questions over benefit for broader groups

KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi

read more